MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+6.98%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$577M
AUM Growth
+$577M
(-0.78%)
Cap. Flow
-$12.6M
Cap. Flow
% of AUM
-2.19%
Top 10 Holdings %
Top 10 Hldgs %
45.32%
Holding
51
New
8
Increased
10
Reduced
20
Closed
7
Top Buys
| 1 |
Tarsus Pharmaceuticals
TARS
|
$13.8M |
| 2 |
Dyne Therapeutics
DYN
|
$13.8M |
| 3 |
Akebia Therapeutics
AKBA
|
$10.5M |
| 4 |
DBVT
DBV Technologies
DBVT
|
$9.65M |
| 5 |
Edgewise Therapeutics
EWTX
|
$8.07M |
Top Sells
| 1 |
Lantheus
LNTH
|
$22.7M |
| 2 |
United Therapeutics
UTHR
|
$18.2M |
| 3 |
ITOS
iTeos Therapeutics
ITOS
|
$10.4M |
| 4 |
Twist Bioscience
TWST
|
$10.3M |
| 5 |
Natera
NTRA
|
$9.82M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Wave Life Sciences
WVE
$1.26B
| $9.78M | 1.7% |
1,505,262
-4,318
| -0.3% | -$28.1K |
|
|
DBVT
27
DBV Technologies
DBVT
$257M
| $9.65M | 1.67% |
+1,054,504
| New | +$9.65M |
|
28
Context Therapeutics
CNTX
$76.1M
| $9.64M | 1.67% |
14,705,882
| – | – |
|
29
Rocket Pharmaceuticals
RCKT
$356M
| $9.56M | 1.66% |
3,903,081
+2,284,816
| +141% | +$5.6M |
|
30
Replimune Group
REPL
$472M
| $9.14M | 1.58% |
983,780
-3,256
| -0.3% | -$30.2K |
|
31
Nuvation Bio
NUVB
$1.09B
| $9.01M | 1.56% |
4,622,590
-29,653
| -0.6% | -$57.8K |
|
32
Stoke Therapeutics
STOK
$1.11B
| $8.96M | 1.55% |
789,698
+95,710
| +14% | +$1.09M |
|
33
Solid Biosciences
SLDB
$435M
| $7.96M | 1.38% |
1,634,569
-7,787
| -0.5% | -$37.9K |
|
34
Relay Therapeutics
RLAY
$674M
| $7.9M | 1.37% |
2,282,680
-13,244
| -0.6% | -$45.8K |
|
35
Cartesian Therapeutics
RNAC
$263M
| $7.13M | 1.24% |
686,007
-104,772
| -13% | -$1.09M |
|
36
Taysha Gene Therapies
TSHA
$786M
| $6.82M | 1.18% |
+2,953,562
| New | +$6.82M |
|
37
Sarepta Therapeutics
SRPT
$1.95B
| $5.5M | 0.95% |
+321,696
| New | +$5.5M |
|
38
Soleno Therapeutics
SLNO
$3.56B
| $4.19M | 0.73% |
+50,000
| New | +$4.19M |
|
39
Veru
VERU
$50.1M
| $2.86M | 0.5% |
4,911,948
-1,680,779
| -25% | -$978K |
|
40
Werewolf Therapeutics
HOWL
$60.4M
| $2.63M | 0.45% |
2,408,810
| – | – |
|
41
Design Therapeutics
DSGN
$327M
| $1.87M | 0.32% |
555,187
-7,756
| -1% | -$26.1K |
|
42
Repare Therapeutics
RPTX
$73.9M
| $1.14M | 0.2% |
819,924
| – | – |
|
|
ADAP
43
Adaptimmune Therapeutics
ADAP
$14.7M
| $1.06M | 0.18% |
4,411,821
-482,523
| -10% | -$116K |
|
44
Arcellx
ACLX
$3.88B
| $2.44K | ﹤0.01% |
+37
| New | +$2.44K |
|
45
ALX Oncology
ALXO
$55.7M
| – | – |
-550,000
| Closed | -$343K |
|
46
IDEAYA Biosciences
IDYA
$2.3B
| – | – |
-430,161
| Closed | -$7.05M |
|
47
Iovance Biotherapeutics
IOVA
$807M
| – | – |
-2,708,582
| Closed | -$9.02M |
|
|
ITOS
48
DELISTED
iTeos Therapeutics
ITOS
| – | – |
-1,745,943
| Closed | -$10.4M |
|
|
49
Lantheus
LNTH
$3.77B
| – | – |
-232,387
| Closed | -$22.7M |
|
|
50
Twist Bioscience
TWST
$1.62B
| – | – |
-261,215
| Closed | -$10.3M |
|